(Boursier.com) — The Board of Directors of Sanofi has decided to propose, as part of the next General Meeting of Shareholders, scheduled for April 30, the renewal of the mandates of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as directors independent.
Diane Souza (member of the Audit Committee and the Compensation Committee) and Thomas Südhof (Chairman of the Scientific Committee) are leaving the Board of Directors at the end of their second mandates. The President warmly “thanked them for their valuable contribution to the Board of Directors and the specialized committees to which they belonged during their mandates”.
The Chairman specified that in order to best prepare for the end, in 2025, of the mandate as director of Fabienne Lecorvaisier (Chairman of the Audit Committee), the Board of Directors will be temporarily composed of 17 members from General meeting of shareholders of April 30, 2024.
Clotilde Delbos is currently a director of Axa and Alstom. Anne-Françoise Nesmes is currently Chief Financial Officer of Smith + Nephew PLC, a role from which she will resign at the end of Q1 2024. John Sundy is currently Chief Medical Officer and Head of Research and Development at Seismic Therapeutic, a machine learning company in Immunology, and Assistant Professor of Medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine in the United States.
The composition of the specialized committees of the Board will be reviewed following the General Meeting of Shareholders scheduled for April 30, 2024.
©2024 Boursier.com